

4 October 2024

Dear Shareholder

2024 ANNUAL GENERAL MEETING

Cleo Diagnostics Ltd (ASX: COV) ("the Company") advises that the 2024 Annual General Meeting of the shareholders of the Company is scheduled to be held at the offices of FB Rice, Level 33, 477 Collins Street, Melbourne Victoria 3000 on Wednesday, 27 November 2024 at 10.30am (AEDT) ("the Meeting").


In accordance with section 110D(1) of the Corporations Act 2001 (Cth) (Corporations Act), the Company will not be sending hard copies of the NOM to shareholders unless a shareholder has requested a hardcopy of the NOM or made an election for the purposes of 110E of the Corporations Act to receive documents from the Company in physical form. The NOM is made available to shareholders electronically. The Notice of the Meeting can be viewed, accessed and downloaded at <https://www.cleodx.com/asx-announcements> or via the following direct link to the ASX announcements platform of the Company: <https://www.asx.com.au/markets/company/cov>

Those shareholders who receive their company communications in the post will therefore receive a printed copy of this announcement and their personalised proxy form.

Alternatively, shareholders who receive their communications electronically will receive an email from the Company's share registry, Xcend Pty Ltd, with links directing them to this notice and the online voting portal <https://investor.xcend.app>

Shareholders are strongly encouraged to vote by lodging a directed proxy appointing the Chairman before 10.30am (AEDT) on Monday 25 November 2024. A personalised proxy form is enclosed. Proxies can be lodged in accordance with instructions in the enclosed personalised proxy form.

The Company thanks shareholders for their ongoing support.



Ms Pauline Moffatt
Company Secretary

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors
Chair and Non-Executive Director: **Adrien Wing**
Chief Executive Officer and Executive Director: **Dr Richard Alliman**
Chief Scientific Officer and Executive Director: **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor: **Professor Tam Jobling**
Non-Executive Director: **Lucinda Nolan**

[cleodx.com](https://www.cleodx.com)